Compare · AZN vs PRTA
AZN vs PRTA
Side-by-side comparison of AstraZeneca PLC (AZN) and Prothena Corporation plc (PRTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and PRTA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $261.92B, about 577.7x PRTA ($453.4M).
- Over the past year, AZN is down 10.3% and PRTA is up 37.6% - PRTA leads by 47.9 points.
- AZN has hit the wire 12 times in the past 4 weeks while PRTA has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 22 for PRTA).
- Company
- AstraZeneca PLC
- Prothena Corporation plc
- Price
- $168.85-0.24%
- $8.65+2.06%
- Market cap
- $261.92B
- $453.4M
- 1M return
- -5.56%
- +4.59%
- 1Y return
- -10.32%
- +37.63%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 22
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest PRTA
- Large owner Scully William P bought $157,990 worth of Ordinary Shares (20,000 units at $7.90), increasing direct ownership by 3% to 756,000 units (SEC Form 4)
- Large owner Scully William P gifted 325,000 units of Ordinary Shares, decreasing direct ownership by 31% to 736,000 units (SEC Form 4)
- Large owner Scully William P bought $1,021,225 worth of Ordinary Shares (125,000 units at $8.17), increasing direct ownership by 13% to 1,061,000 units (SEC Form 4)
- New insider Isaacs Michael John claimed ownership of 48,825 units of Ordinary Shares (SEC Form 3)
- SEC Form 144 filed by Prothena Corporation plc
- Large owner Scully William P bought $465,295 worth of Ordinary Shares (50,000 units at $9.31), increasing direct ownership by 6% to 936,000 units (SEC Form 4)
- Large owner Scully William P bought $471,300 worth of Ordinary Shares (50,000 units at $9.43), increasing direct ownership by 6% to 886,000 units (SEC Form 4)
- Large owner Scully William P bought $981,300 worth of Ordinary Shares (100,000 units at $9.81), increasing direct ownership by 14% to 836,000 units (SEC Form 4)
- SEC Form 4 filed by Director Welch Daniel G
- SEC Form 4 filed by Director Selkoe Dennis J.